Fig. 1From: GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapyCRISPR/Cas9 mechanism of action. Cas9 and sgRNA vehiculation to edit the nuclear target sequence by nanoparticles when assembled to form RNP complex (left); delivery of the elements as single plasmids of expression through lipo-assisted transfection reagent or by electroporation (center); Viral transduction of Cas9 and sgRNA carrying vector (right). DNA repair machinery (NHEJ, HDR) is activated when the nucleus is reached by the CRISPR/Cas9 systemBack to article page